This complete re-evaluation of the Men’s Health market focuses on the following prescription drug treatment segments:
- Men’s Cancer
- Men’s Sexual Dysfunction
- Men’s Sexually Transmitted Diseases
- Men’s Urinary Conditions
The report covers drugs used for the treatment of prostate cancer, testicular cancer, impotence, premature ejaculation, and benign prostatic hyperplasia (BPH), urinary incontinence, and STD’s such as HIV, herpes, and genital warts. For each segment, revenues and forecasts are made by type of drug through 2010; competitive market share of the leading suppliers are estimated for 2005 and projected to 2010 based on likely market entrants and patent expiry; and a geographical breakdown (U.S. vs non-U.S.) is provided through 2010.
The report includes epidemiologic information on the various conditions (U.S. and worldwide) and reviews the issues and trends—business, clinical, regulatory, and social—that are shaping the future of this market.